help button home button Endocrine Society Endocrinology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lopez, F. J.
Right arrow Articles by Negro-Vilar, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lopez, F. J.
Right arrow Articles by Negro-Vilar, A.

Endocrinology, Vol 124, 527-535, Copyright © 1989 by Endocrine Society


ARTICLES

Role of dopamine and vasoactive intestinal peptide in the control of pulsatile prolactin secretion

FJ Lopez, JR Dominguez, F Sanchez-Franco and A Negro-Vilar
Reproductive Neuroendocrinology Section, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709.

The present studies were designed to obtain a detailed characterization of pulsatile PRL secretory patterns under basal conditions and to explore the role of dopamine (DA) and vasoactive intestinal peptide (VIP) in the genesis of PRL pulses. Adult intact male rats received chronic indwelling jugular canula and were bled at 3-min intervals for periods ranging from 90-150 min. Pulse analysis was performed using the algorithm Detect. Blockade of DA receptors with domperidone, pimozide, or haloperidol resulted in a 2-fold increase in PRL pulse frequency, with no change in pulse duration. All quantitative parameters, i.e. peak and trough values, pulse amplitude, and area under the pulse, were significantly increased after dopaminergic blockade. Blockade of endogenous VIP activity was achieved by passive immunization with a potent VIP antiserum. This treatment, by itself, did not modify basal PRL levels or PRL pulsatility parameters. However, when VIP antiserum was administered in combination with domperidone, a reduction in all quantitative pulse parameters was observed. Heterogeneity of PRL pulses was evaluated by frequency distribution analysis, using the area under the pulse divided by basal secretion, to evaluate the mass of hormone secreted per pulse normalized to the basal rate of secretion. Untreated animals presented pulses within a range of different masses. Dopaminergic blockade resulted in a great reduction in big mass pulses, and the distribution of pulses was restricted primarily to small mass pulses. The increased pulse frequency after dopaminergic blockade, therefore, results mainly from an increase in the appearance of small mass pulses. These results indicate that DA exerts a tonic inhibitory action on the frequency as well as the qualitative parameters of PRL pulses. They also suggest that big mass PRL pulses are dopaminergic in origin, i.e. they may result from temporary interruptions in DA activity. Small mass PRL pulses appear to result from other neural stimulatory inputs. Endogenous VIP enhances quantitative PRL pulse parameters, but this activity is only apparent after removal of DA inhibition.


This article has been cited by other articles:


Home page
J Mol EndocrinolHome page
M Fernandez, F Sanchez-Franco, N Palacios, I Sanchez, and L Cacicedo
IGF-I and vasoactive intestinal peptide (VIP) regulate cAMP-response element-binding protein (CREB)-dependent transcription via the mitogen-activated protein kinase (MAPK) pathway in pituitary cells: requirement of Rap1
J. Mol. Endocrinol., June 1, 2005; 34(3): 699 - 712.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. A. Everson and W. R. Crowley
Reductions in circulating anabolic hormones induced by sustained sleep deprivation in rats
Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E1060 - E1070.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
A. ZOLI, E. M. FERLISI, M. LIZZIO, L. ALTOMONTE, L. MIRONE, A. BARINI, F. SCUDERI, F. BARTOLOZZI, and M. MAGARO
Prolactin/Cortisol Ratio in Rheumatoid Arthritis
Ann. N.Y. Acad. Sci., June 1, 2002; 966(1): 508 - 512.
[Abstract] [Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
I. C. CHIKANZA
Prolactin and Neuroimmunomodulation: In Vitro and in Vivo Observations
Ann. N.Y. Acad. Sci., June 22, 1999; 876(1): 119 - 130.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1989 by The Endocrine Society